Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda and Taxotere in High-risk Breast Cancer
NCT00089479Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2002
- Primary completion
- Jun 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Roche. Started Aug 2002; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00089479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089479.